Extension Study of Idelalisib in Participants With Chronic Lymphocytic Leukemia (CLL) Who Participated in GS-US-312-0116 (NCT01539512)
A Phase 3, Double-Blind Extension Study Evaluating the Efficacy and Safety of Two Different Dose Levels of Single-Agent Idelalisib (GS-1101) for Previously Treated Chronic Lymphocytic Leukemia A Companion Trial to Study GS-US-312-0116: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Idelalisib (GS-1101) in Combination With Rituximab for Previously Treated Chronic Lymphocytic Leukemia
Sponsor: Gilead Sciences
Terminated
This trial was terminated. No reason was provided.
Other terminated trials from Gilead Sciences
Other Chronic Lymphocytic Leukemia trials with similar outcome
This PHASE3 trial investigates Chronic Lymphocytic Leukemia and is currently terminated or withdrawn. Gilead Sciences leads this study, which shows 12 recorded versions since 2012 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
12 versions recorded-
Sep 2025 — Present [monthly]
Terminated PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Terminated PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE3
-
Jan 2021 — Jul 2024 [monthly]
Terminated PHASE3
-
Sep 2019 — Jan 2021 [monthly]
Terminated PHASE3
Status: Completed → Terminated
▶ Show 7 earlier versions
-
Nov 2018 — Sep 2019 [monthly]
Completed PHASE3
-
Aug 2018 — Nov 2018 [monthly]
Completed PHASE3
-
Jul 2018 — Aug 2018 [monthly]
Completed PHASE3
Status: Active Not Recruiting → Completed
-
Jun 2018 — Jul 2018 [monthly]
Active Not Recruiting PHASE3
-
Nov 2017 — Jun 2018 [monthly]
Active Not Recruiting PHASE3
-
Feb 2017 — Nov 2017 [monthly]
Active Not Recruiting PHASE3
-
Jan 2017 — Feb 2017 [monthly]
Active Not Recruiting PHASE3
First recorded
Oct 2012
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Gilead Sciences
For direct contact, visit the study record on ClinicalTrials.gov .